VRPX Stock Overview
A preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Virpax Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.61 |
| 52 Week High | US$7.20 |
| 52 Week Low | US$0.36 |
| Beta | 1.09 |
| 11 Month Change | -9.65% |
| 3 Month Change | -33.46% |
| 1 Year Change | -91.23% |
| 33 Year Change | -98.52% |
| 5 Year Change | n/a |
| Change since IPO | -99.06% |
Recent News & Updates
Shareholder Returns
| VRPX | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -19.1% | -6.0% | -2.1% |
| 1Y | -91.2% | 9.6% | 30.2% |
Return vs Industry: VRPX underperformed the US Pharmaceuticals industry which returned 9.6% over the past year.
Return vs Market: VRPX underperformed the US Market which returned 30.2% over the past year.
Price Volatility
| VRPX volatility | |
|---|---|
| VRPX Average Weekly Movement | 19.3% |
| Pharmaceuticals Industry Average Movement | 9.7% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.5% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: VRPX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: VRPX's weekly volatility has decreased from 28% to 19% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 7 | Jay Dhaliwal | www.virpaxpharma.com |
Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain. The company’s preclinical stage product candidates also comprise AnQlar, an anti-viral barrier to prevent or reduce the risk or the intensity of viral infections in humans, including influenza and SARS-CoV-2; and NobrXiol, an investigational formulation to be delivered via the nasal route to enhance cannabidiol transport to the brain.
Virpax Pharmaceuticals, Inc. Fundamentals Summary
| VRPX fundamental statistics | |
|---|---|
| Market cap | US$3.00m |
| Earnings (TTM) | -US$13.24m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.2x
P/E RatioIs VRPX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VRPX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$13.24m |
| Earnings | -US$13.24m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.71 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did VRPX perform over the long term?
See historical performance and comparison